Agency Night Renew Rx review: the current formula and what membership includes

The product page presents Night Renew Rx with a 24 g quantity and a 60-day supply description. The pricing article, dated August 28, 2026, explicitly identifies it as formerly Future Formula. Together, the two pages establish the current identity more clearly than the older wording still present in the product’s web address.

That does not establish that every earlier Future Formula prescription had the same composition as today’s Night Renew. Personalized prescriptions can differ. It also means an older quoted price should not replace the current $130 subscription-order figure. The options comparison offers a broader starting point, but the current Agency description should control this product’s name and offer.

Agency’s ingredient description lists possible ingredients including tretinoin, dexpanthenol, estriol, tranexamic acid, azelaic acid, glycerin and niacinamide. The language is conditional: the formula may include these ingredients, subject to consultation. It also states that not all formulas contain tretinoin. The menu therefore cannot be read as the contents of every prescribed container.

This matters for a review centered on fine lines and tretinoin. An Agency prescription without tretinoin would be a different combination from one containing it, even under the same product name. Our Hers review and Hims review are separate product readings, rather than substitutes for the composition of a particular Night Renew formula.

The inactive declaration names ingredients including water, aloe, caprylic/capric triglyceride, polyacrylamide and preservatives. More importantly, Agency says all Night Renew formulas contain propylene glycol, while formulas containing tretinoin also contain BHT. Those are two differently scoped statements: one applies across the named range; the other depends on the active ingredient being present.

A disclosed base helps make the product description concrete, but it does not establish comfort for every person or measure the active ingredients in an individual prescription. The FDA’s explanation concerns the separate regulatory status of compounded drugs. A fuller ingredient list is useful disclosure; it does not convert a personalized combination into an FDA-approved finished product.

The current comparison claim says the available tretinoin range is up to 40% stronger and 80% gentler than a retail pharmacy. The comparison wording does not identify a particular comparator product, study population or measure of gentleness. These are Agency’s advertised comparisons, not independently established clinical rankings between two specified finished preparations.

Strength and tolerability are also different questions. A wider set of possible prescriptions does not, by itself, show that the supplied preparation produces a larger visible improvement or fewer reactions. The RENOVA label and our label guide illustrate why the exact preparation and assessed outcome matter. That evidence cannot be carried across to whichever ingredients an Agency provider chooses.

The membership explanation includes one consultation credit with each shipment. Those credits allow a one-to-one medical conversation with the dermatology provider, do not expire, and can be supplemented with consultations priced at $10 each. This is more specific than a general claim of ongoing access, and it helps explain the contact arrangement attached to the prescription.

The same article lists Night Renew at $130 per subscription order, with shipping included and tax where applicable. Its supply duration describes the commercial package, not a personal application calendar. The stated benefits also include requesting formula adjustments through the provider. They do not establish an unlimited number of medical conversations, an actual response time or the outcome of a future assessment.

The testimonial area includes experiences involving Night Renew and another prescription product. A favorable account may describe the person’s overall experience, but it cannot separate the contribution of Night Renew from the other preparation. It also does not tell us whether the prescription in that account matches another person’s personalized ingredient combination.

The FTC’s endorsement guidance requires honest experience and cautions against performance claims without the necessary proof. That is advertising context, not a finding about Agency’s customers. The fine versus deep wrinkles guide adds another useful distinction: a more radiant or even-looking complexion is not automatically evidence of a measured change in deeper wrinkles.

Night Renew’s product description covers fine lines, firmness, uneven tone, redness and radiance. Those are the brand’s intended appearance benefits across a personalized range. They do not supply separate controlled results for every possible combination, particularly when the active menu includes several very different ingredients and may exclude tretinoin altogether.

Agency’s useful strengths as a public offer are its current quantity, base declaration and defined consultation-credit policy. Its less settled point is the link between a specific finished formula and the broad comparison claims. The FDA compound distinction remains separate from both. Knowing the actual prescription would sharpen the review; the product name alone cannot answer every ingredient or outcome question.